Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial

Clinical and Experimental Rheumatology

Volumn 32, Issue 5, 2014, Pages 689-696

  Rider, Lisa G ^a   Yip, Adrienne L ^a   Horkayne Szakaly, Iren ^b   Volochayev, Rita ^a   Shrader, Joseph A ^c   Turner, Maria L ^d   Kong, Heidi H ^d   Jain, Minal S ^c   Jansen, Anna V ^a   Oddis, Chester V ^e   Fleisher, Thomas A ^c   Miller, Frederick W ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b Neuropathology and Ophthalmic Pathology Joint Pathology Center   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Biological therapy; CD20 depletion; Clinical trial; Dermatomyositis; Idiopathic inflammatory myopathies; Juvenile dermatomyositis; Outcome assessment; Polymyositis; Rituximab

Indexed keywords

PLACEBO; RITUXIMAB; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; B LYMPHOCYTE; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL IMPROVEMENT; CLINICAL STUDY; DATA BASE; DERMATOMYOSITIS; DISEASE COURSE; DRUG RESPONSE; FATIGUE; FEMALE; GASTROINTESTINAL TRACT; HUMAN; JUVENILE DERMATOMYOSITIS; LABORATORY TEST; LYMPHOCYTE DEPLETION; MALE; MULTICENTER STUDY; MUSCLE FUNCTION; MUSCLE STRENGTH; NATIONAL HEALTH ORGANIZATION; OUTCOMES RESEARCH; POLYMYOSITIS; QUALITY OF LIFE; RESPIRATORY SYSTEM; SCHOOL CHILD; SKIN EXAMINATION; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DRUG EFFECTS; HEALTH STATUS INDICATOR; IMMUNOLOGY; MIDDLE AGED; MYOSITIS; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SKIN; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; BIOLOGICAL MARKERS; CHILD; FEMALE; HEALTH STATUS INDICATORS; HUMANS; MALE; MIDDLE AGED; MUSCLE STRENGTH; MYOSITIS; PREDICTIVE VALUE OF TESTS; QUESTIONNAIRES; RECOVERY OF FUNCTION; REMISSION INDUCTION; SKIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84907578519     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. BUCH MH, SMOLEN JS, BETTERIDGE N et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70: 909-20.
2. STONE JH, MERKEL PA, SPIERA R et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221-32.
3. TONY HP, BURMESTER G, SCHULZE-KOOPS H et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther 2011; 13: R75.
4. GÜRCAN HM, KESKIN DB, STERN JN, NITZBERG MA, SHEKHANI H, AHMED AR. A review of the current use of rituximab in autoimmune diseases. International Immunopharmacology 2009; 9: 10-25.
5. HUANG H, BENOIST C, MATHIS D. Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis. Proc Natl Acad Sci USA 2010; 107: 4658-63.
6. LEVINE TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005; 52: 601-7.
7. COOPER MA, WILLINGHAM DL, BROWN DE, FRENCH AR, SHIH FF, WHITE AJ. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum 2007; 56: 3107-11.
8. BADER-MEUNIER B, DECALUWE H, BARNER-IAS C et al. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry. J Rheumatol 2011; 38: 1436-40.
9. RIOS FR, CALLEJAS RUBIO JL, SANCHEZ CD, SAEZ MORENO JA, ORTEGO CN. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature. Clin Exp Rheumatol 2009; 27: 1009-16.
10. RIDER LG, GIANNINI EH, BRUNNER HI et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004; 50: 2281-90.
11. ODDIS CV, REED AM, AGGARWAL R et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo-phase trial. Arthritis Rheum 2013; 65: 314-24.
12. CHUNG L, GENOVESE MC, FIORENTINO DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007; 143: 763-7.
13. BOHAN A, PETER JB. Polymyositis and dermatomyositis. Parts 1 and 2. N Engl J Med 1975; 292: 344-7,-3403-407.
14. LINKLATER H, PIPITONE N, ROSE MR et al. Classifying idiopathic inflammatory myopathies: comparing the performance of six existing criteria. Clin Exp Rheumatol 2013; 31: 767-9.
15. ESPADA G, MALDONADO COCCO JA, FERTIG N, ODDIS CV. Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol 2009; 36: 2547-51.
16. RIDER LG, WERTH VP, HUBER AM et al. Measures of adult and juvenile dermatomyositis, polymyositis, and includsion body myositis. Arthritis Care Res 2011; 63: S118-S157.
17. ISENBERG DA, ALLEN E, FAREWELL V et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 2004; 43: 49-54.
18. FELSON DT, ANDERSON JJ, LANGE ML, WELLS G, LAVALLEY MP. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum 1998; 41: 1564-70.
19. HASIJA R, PISTORIO A, RAVELLI A et al. Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: an international multicenter PRINTO study. Arthritis Rheum 2011; 63: 3142-52.
20. RIDER LG, KOZIOL D, GIANNINI EH et al. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken) 2010; 62: 465-72.
21. SIEGEL K, HICKS J, KOZIOL D, GERBER L, RIDER L. Walking ability and its relationship to lower-extremity muscle strength in children with idiopathic inflammatory myopathies. Arch Phys Med Rehabil 2004; 85: 767-71.
22. VARNI JW, SEID M, KNIGHT TS, BURWINKLE T, BROWN J, SZER IS. The PedsQL in pediatric rheumatology: Reliability, validity, and responsiveness of the Pediatric Quality of Life Inventory Generic Core Scales and Rheumatology Module. Arthritis Rheum 2002; 46: 714-25.
23. CAMPBELL RC, SCOTT DL, KIELY PD, GORDON P. Fatigue in idiopathic inflammatory myopathy (IIM): prevalence, impact and association with quality of life. Arthritis and Rheumatism 2011; 63: S89.
24. TEIXEIRA-SALMELA LF, OLNEY SJ, NADEAU S, BROUWER B. Muscle strengthening and physical conditioning to reduce impairment and disability in chronic stroke survivors. Arch Phys Med Rehabil 1999; 80: 1211-2328.
25. BLEESING JJ, SOUTO-CARNEIRO MM, SAVAGE WJ et al. Patients with chronic granulomatous disease have a reduced peripheral blood memory B cell compartment. J Immunol 2006; 176: 7096-103.
26. SANZ I, LEE FE. B cells as therapeutic targets in SLE. Nat Rev Rheumatol 2010; 6: 326-37.
27. YAO L, GAO N. Fat-corrected T2 measurement as a marker of active muscle disease in inflammatory myopathy. Am J Roentgenol 2012; 198: W475-81.
28. BELLAMY N. Musculoskeletal Clinical Metrology. Dordrecht, Kluwer Academic Publishers, 1993.
29. RIDER LG, GIANNINI EH, HARRIS-LOVE M et al. Defining Clinical Improvement in Adult and Juvenile Myositis. J Rheumatol 2003; 30: 603-17.
30. ODDIS CV, RIDER LG, REED AM et al. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 2005; 52: 2607-15.
31. MUSCLE STUDY GROUP: A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 2011; 70: 427-36.
32. VOS K, THURLINGS RM, WIJBRANDTS CA, VAN SD, GERLAG DM, TAK PP. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum 2007; 56: 772-8.
33. KAVANAUGH A, ROSENGREN S, LEE SJ et al. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Ann Rheum Dis 2008; 67: 402-8.
34. SILVERMAN GJ, BOYLE DL. Understanding the mechanistic basis in rheumatoid arthritis for clinical response to anti-CD20 therapy: the B-cell roadblock hypothesis. Immunol Rev 2008; 223: 175-85.
35. BOUMANS MJ, THURLINGS RM, GERLAG DM, VOS K, TAK PP. Response to rituximab in patients with rheumatoid arthritis in different compartments of the immune system. Arthritis Rheum 2011; 63: 3187-94.
36. WALSH CA, FEARON U, FITZGERALD O, VEALE DJ, BRESNIHAN B. Decreased CD20 expression in rheumatoid arthritis synovium following 8 weeks of rituximab therapy. Clin Exp Rheumatol 2008; 26: 656-8.
37. RATERMAN HG, VOSSLAMBER S, DE RIDDER S et al. The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther 2012; 14: R95.
38. SALVADOR FB, ISENBERG DA. Outcome predictors in patients with idiopathic inflammatory myopathies. Clin Exp Rheumatol 2012; 30: 980.
39. AGGARWAL R, BANDOS A, REED AM et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheum 2013.
40. ROTHMAN KJ: No adjustments are needed for multiple comparisons. Epidemiology 1990; 1: 43-6.